Inhibrx's Ozekibart Nears FDA Decision for Rare Bone Cancer

Event summary

  • FDA accepted Inhibrx's BLA for ozekibart in chondrosarcoma with no review issues identified
  • PDUFA goal date set for April 14, 2027
  • Ozekibart demonstrated 52% reduction in disease progression risk vs. placebo in ChonDRAgon trial
  • If approved, ozekibart would be first FDA-approved treatment for unresectable/metastatic chondrosarcoma
  • Inhibrx would gain its first commercial product with ozekibart approval

The big picture

This FDA filing represents a critical milestone for Inhibrx as it seeks to commercialize its first product. The acceptance of the BLA for ozekibart highlights the company's ability to develop targeted therapies for rare cancers with high unmet medical needs. If approved, ozekibart would establish Inhibrx as a player in the oncology space, potentially opening doors to partnerships or acquisitions. The company's focus on protein engineering platforms positions it to develop additional therapeutic candidates beyond ozekibart.

What we're watching

Regulatory Pathway
Whether the FDA will require additional data or impose restrictions during the review process
Commercialization Strategy
How Inhibrx plans to position ozekibart in the rare disease market given its orphan drug status
Pipeline Expansion
The progress of ozekibart's combination therapy trials in Ewing sarcoma and colorectal cancer